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The majority (>90%) of paediatric HIV infections 
occur in sub-Saharan Africa.[1,2] In South Africa (SA), 
programmes to reduce vertical transmission began in 
2003, with combination antiretroviral therapy (cART) 
becoming available in the public sector in 2004. 
Many children in whom cART was initiated already had advanced 
HIV disease. Early ART from 7 to 8 weeks of age was only instituted 
in 2010.[3] Respiratory disease is a major cause of morbidity and is the 
most important cause of mortality in HIV-positive children.[4] A high 
prevalence of chronic lung disease (CLD) was recently recognised in 
perinatally infected adolescents.[5] 
There are no uniform diagnostic criteria for CLD in children. [6-13] 
Chronic respiratory symptoms such as a chronic cough for at least 
3 months of the year, or cough with associated symptoms and 
chronic radiological signs have been used.[7] In a recent study of 
CLD in HIV-infected adolescents, the diagnostic criteria for CLD 
included a combination of symptoms, clinical signs, radiological 
manifestations, exercise tests, oxygen saturations, spirometry and 
echocardiographic findings.[5] In this study, at least a third of 
patients with chronic respiratory impairment would not have 
been identified had cough-predominant diagnostic criteria been 
used. Many diagnostic investigations required to substantiate 
the diagnosis are often unavailable in the areas most affected by 
HIV. Also, tests to separate cardiovascular from respiratory causes 
cannot always be performed. Additional clinical predictors of 
chronic respiratory impairment could be useful in resource-limited 
settings to enable healthcare workers to recognise children with 
CLD. 
There are a few studies of CLD in HIV-infected children and 
adolescents. In a narrative review, the most likely aetiologies included 
pulmonary tuberculosis (PTB), lymphoid interstitial pneumonitis 
(LIP), persistent or recurrent pneumonia and bronchiectasis. [12] More 
recently, small airway disease has been described in adolescents. [5] 
Other aetiologies include interstitial lung disease (ILD) and 
malignancy.[12] In a study by Jeena et al.,[7] predating cART availability, 
71% of young children investigated for persistent lung disease 
(defined as persistence of clinical and radiological findings after at 
least 1 month of initial treatment) were HIV-infected. In those with 
symptoms for more than 3 months, LIP (57%) was the most important 
cause, followed by PTB (29%). A review of the chest radiographs 
of HIV-infected children in the USA, again predating early cART, 
showed that chronic radiological changes had a cumulative incidence 
of 33% by 4 years of age.[11] More recently, Pitcher et al.[14] showed that 
in children with a median age of 23.8 months and limited access to 
cART, only 16% of 330 children from Cape Town had normal chest 
radiographs, with 169 (51%) having severe radiological abnormalities.
Objective
To describe the symptoms, signs and lung function in HIV-infected 
children evaluated for CLD seen at Tygerberg Children’s Hospital in 
Cape Town, Western Province, SA, a region with a high prevalence 
of both HIV and TB. 
Methods
Subjects in whom CLD was suspected because of chronic symptoms 
and/or signs or with a history of recurrent pneumonia participated 
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in a cross-sectional study. Clinical evaluation 
and lung function tests were accompanied 
by a complete retrospective chart review. 
The clinical evaluations were performed 
over 10 months, from May 2005 to February 
2006. The definition used for CLD disease 
was a chronic cough and/or respiratory 
or radiological signs present for at least 
3 months. Vital signs were obtained from 
the clinical charts on the same day that a 
single investigator (H C Weber) undertook 
the clinical examination. Transcutaneous 
oxy gen saturation measurements were 
not consistently taken and were therefore 
excluded from analysis. The World Health 
Organization (WHO) growth standards 
were used for weight-for-age z-scores 
(WAZ), height-for-age z-scores (HAZ) and 
weight-for-height z-scores (WHZ). Children 
with z-scores two standard deviations (SDs) 
below the mean WAZ were classified as 
underweight and two SDs below the mean 
HAZ were classified as stunted.[15] The 
lowest recorded CD4 percentage and highest 
recorded log viral load (VL) were obtained 
from clinical records.
A Jaeger Masterscreen pneumotachometer 
system (Erich Jaeger, Germany), with daily 
volume calibration as per American Thoracic 
Society (ATS)/European Respiratory Society 
(ERS) protocol was used for lung function 
tests.[16] Ability to perform adequate lung 
function tests was determined by the child’s 
ability to produce an acceptable flow volume 
loop according to ATS/ERS criteria.[16] The 
highest forced expiratory volume in 1 second 
(FEV1) value was recorded and Polgar’s 
equation was used to calculate reference 
values. [17] 
Background and clinical characteristics 
were summarised using frequency and 
percentage for categorical data, and median 
and interquartile range (IQR) for continuous 
data. A respiratory rate ratio was developed 
to allow comparison of respiratory rates 
across different age groups. Each child’s 
respiratory rate was divided by the upper 
limit of normal respiratory rate for that 
age. [18] 
Spearman’s correlation coefficients were 
used to measure the associations between 
the percentage predicted FEV1 (FEV1%) 
and clinical characteristics measured 
on a continuous scale. For continuous 
variables, mean FEV1% was compared 
using t-tests. Univariable and multivariable 
linear regressions were used to determine 
predictors for poor outcome in lung function 
tests. Factors most strongly associated with 
FEV1% in univariable analysis were retained 
for the multivariable analyses. The data were 
entered into an Access (Microsoft, USA) 
database, and all the statistical procedures 
were performed using STATA statistical 
software, version 10 (StataCorp, USA). Tests 
of significance were two-tailed, and a p-value 
<0.05 was considered significant. 
Informed consent was obtained from the 
parents or legal guardians of the children. 
Institutional Review Board approval was 
obtained from the Health Research Ethics 
Committee at Stellenbosch University. 
Results
Clinical features
Fifty-six children were studied. Table 1 
shows the baseline demographic and clinical 
characteristics. Median age was 5 years. 
Of the 36 cases previously hospitalised for 
pneumonia, 27 (74%) had two or more and 
13 (37%) had three or more hospitalisations. 
The majority (93%) had been previously 
treated for PTB, 60% on two or more 
occasions. Forty-seven per cent were stunted 
and 31% were underweight for age. 
The median period on ART was 9.8 (IQR 
1.1 - 19.5) months. There was documenta-
tion of inhaled bronchodilator use in 8 
(16%) and inhaled corticosteroids in 5 (10%) 
children. 
Lung function 
Twenty-seven children (48%) performed 
adequate lung function tests. The median 
FEV1% was 60% (IQR 45.3 - 86.3%). Only 
Table 1. Demographic data, background information, associated diagnoses and 
laboratory findings of HIV-infected children (N=56)
Demographic data Total group, n* (%) Lung functions only, n (%) 
Total 56 27 
Age (years), median (IQR) 5 (2 - 8) 6 (3 - 8) 
Gender (male) 30 (53.6) 13 (48.2) 
Background information   
Pneumonia requiring hospitalisation 36 (64.0) 15 (55.6) 
Previous TB 50/54 (92.6) 25 (92.6) 
Exercise limitation 28/53 (52.8) 17 (65.4) 
Wheezing 35/54 (64.8) 16 (59.3) 
Snoring 23/49 (46.9) 12 (50.0) 
Any smoking exposure at home 24/53 (45.3) 13 (48.2) 
Recurrent pneumonia 25/53 (47.2) 10 (40.0) 
Clinical characteristics   
Dental caries 14/40 (35.0) 6 (33.3) 
Digital clubbing 23/52 (44.2) 13 (52.0) 
WAZ, median (IQR) –1.92 (–2.65 - –0.77) –1.45 (–2.95 - –0.46) 
HAZ, median (IQR) –1.39 (–2.16 - –0.73) –1.40 (–2.15 - –0.85) 
WHZ, median (IQR) 0.09 (–0.82 - 0.65) 0.01 (–0.80 - –0.70) 
Wheeze 5/54 (9.3) 3 (11.5) 
Hyperinflation 28/52 (53.8) 14 (56.0) 
Respiratory rate ratio, median (IQR) 1.10 (0.96 - 1.36) 1.16 (0.80 - 1.36) 
Associated diagnoses   
Gastro-oesophageal reflux 5/53 (9.4) 2 (8.0) 
Failure to thrive 11/52 (21.2) 6 (24.0) 
Developmental delay 9/53 (17.0) 4 (16.0) 
Hyperpigmented skin lesions 15/51 (29.4) 7 (29.2) 
Asthma 8/56 (14.3) 7 (25.9) 
LIP 28/52 (53.8) 18 (75) 
Laboratory   
CD4%, median (IQR) 13 (8.5 - 16) 13 (8.5 - 15.8) 
VL (log), median (IQR) 5.84 (4.97 - 6.48) 5.94 (5.58 - 6.54) 
WAZ = observed weight – median weight of the reference population / standard deviation value of reference 
population; HAZ = observed height – median height of the reference population / standard deviation value of 
reference population.
*Equation used where denominator differed from total number of subjects in study (N=56).
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5 (18.5%) had a positive bronchodilator response (FEV1% increase 
≥12% post bronchodilator). Clinical signs associated with FEV1% 
in a univariate relationship included admission for pneumonia, 
respiratory rate, clubbing, hyperinflation and hyperpigmented 
skin lesions. There was a significant negative association between 
respiratory rate (respiratory rate ratio) and lung function (FEV1%), 
indicating that a higher respiratory rate was associated with lower 
FEV1% (Fig. 1). All but one child with FEV1% <60% predicted had 
a respiratory rate at the upper limit of normal for age (respiratory 
rate ratio >1). 
The final regression model for clinical signs associated with lung 
function outcome (FEV1%) is shown in Table 2 (p<0.001, adjusted 
R2=0.68). Although respiratory rate ratio was not statistically 
significant in the final model (p=0.10), it was retained owing to its 
clinical relevance and the significant univariate relationship with 
FEV1%. A unit increase in respiratory rate ratio, in the absence of 
other risk factors, was associated with a 26% reduction of estimated 
FEV1%. The presence of hyperinflation, in the absence of other 
risk factors, was associated with a 40% reduction in estimated 
FEV1%. Hyperpigmented skin lesions alone, an easily recognisable 
clinical marker, was associated with a 34% reduction in FEV1%. The 
predictive values of hyperpigmented skin lesions and hyperinflation 
are not unique as there is significant interaction between these 
factors. FEV1 in one subject, having high influence relative to all 
other observations, was determined to be an outlier. After refitting 
the regression model without this observation, our substantive 
conclusions did not change (adjusted R2=0.82, p<0.001). However, 
respiratory rate ratio reached statistical significance (p=0.018). The 
outlier observation was retained in the final regression model. 
Discussion 
There are very few clinical descriptors of clinical and lung function 
parameters in HIV-infected children with CLD. This study highlights 
uniformly poor lung function and some clinical markers for poor 
respiratory function in these children. Multiple linear regression 
analyses indicate that ratios comparing respiratory rate with the 
upper limit of normal for age, hyperinflation and hyperpigmented 
skin lesions are potential indicators of poor lung function. 
The epidemiology of CLD in HIV-infected children and adolescents 
is poorly described. Ferrand et al.[5] reported an 86% prevalence 
of CLD in Zimbabwean adolescent survivors of perinatal HIV 
infection. Rylance et al.[19] similarly described respiratory impairment 
in a group of Malawian HIV-infected adolescents. Our case series is 
in pre-adolescents, suggesting that CLD is already well established in 
childhood. Children and adolescents with CLD most likely represent 
‘slow progressors’ with a more gradual onset of immunosuppression 
after perinatal infection.
PTB was the most frequent comorbid illness in our study (92%), 
with most (60%) requiring anti-TB treatment on two or more 
occasions. Neither the temporal relationship between PTB and 
CLD nor the accuracy of the PTB diagnosis could be established. 
In adolescents with CLD, small-airway disease with concomitant 
bronchiectasis was the main pathological abnormality, more frequent 
than PTB and LIP.[5] Overdiagnosis of PTB could account for the high 
prevalence of previous PTB in our study.
Clinicians should be alerted to identifying HIV-infected children 
and adolescents at increased risk of CLD. Factors identified in the 
history of the patient include a background of recurrent respiratory 
tract infections (47% in our study) or pneumonia. Similarly, in 
a case-controlled study evaluating risk factors for bronchiectasis 
in HIV-infected children, 89.5% of those with bronchiectasis had 
a history of recurrent pneumonia v. 8.8% in the control group 
(p≤0.001).[20] Additional aggravating factors identified were exposure 
to tobacco smoke (46%), dental caries (30%) and gastro-oesophageal 
reflux (7%), all being opportunities for intervention to limit further 
lung damage. In a recent review we discussed the challenges of CLD 
and some potential treatments, such as aggressive antibiotic therapy 
and regular immunisations.[21]











Fig. 1. Scatter plot of FEV1% v. respiratory rate ratio (correlation coefficient = 
–0.53, p=0.007).
Table 2. Relationship between FEV1% and clinical variables




Respiratory rate ratio –0.65 0.007 
WAZ 0.09 0.702 
HAZ 0.31 0.148 
WHZ 0.25 0.262 
VL (log) 0.06 0.881 
CD4% 0.35 0.089 
Age –0.01 0.958 
cART duration –0.05 0.801 
Admitted for pneumonia 20.5 (2.2 - 38.9) 0.030 
Exercise limitation 14.8 (–5.8 - 55.4) 0.152 
Snoring 8.8 (–13.1 - 29.5) 0.423 
Clubbing 20.2 (1.0 - 39.4) 0.040 
Wheezing –10.3 (–30.3 - 9.7) 0.298 
Hyperinflation 25.0 (6.5 - 43.5) 0.010 
LIP 18.1 (–6.5 - 42.6) 0.141 
Hyperpigmented skin lesions 22.9 (0.8 - 45.0) 0.043 
*Spearman rank correlation reported for continuous variables and mean difference 
(95% CI) reported for categorical variables. 
Table 3. Final model for multivariable linear regression analysis of 
factors associated with reduced FEV1% in HIV-infected children
Variable β (95% CI) p-value 
Respiratory rate ratio –25.7 (–57.4 - 5.87) 0.103 
Hyperinflation –40.5 (–59.6 - –21.3) 0.000 
Hyperpigmented skin lesions –33.5 (–56.8 - –10.2) 0.008 
Hyperinflation and 
hyperpigmented skin lesions 38.8 (3.80, 73.8) 0.032 
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In the current study, 53% of patients had a history of impaired effort 
tolerance, similar to that reported in HIV-infected adolescents. [5,15] 
Other associated symptoms included previous wheezing (65%) and 
snoring (47%). A significant proportion (>40%) of HIV-infected 
adolescents with CLD had hypoxia, either at rest or with exercise. [5,14] 
In addition, Ferrand et al.[5] documented echocardiographic evidence 
of pulmonary hypertension in 7% of adolescents with CLD. 
Additional cardiac abnormalities are common in HIV-infected 
adolescents, with 67% having echocardiographic evidence of left 
ventricular hypertrophy.[22] Hypoxia and cardiac involvement 
are common in HIV-infected children and adolescents, and their 
evaluation should be a major priority. 
Our case series most likely represents the worst end of the 
spectrum, given that the median FEV1% of 60% of the expected 
value was used as the ‘norm’ for comparison. It is likely that routine 
lung function tests and more sensitive tests of exercise impairment 
will identify more subtle effort intolerance. This study identified 
useful clinical associations with poor lung function, i.e. respiratory 
rate, hyperinflation and hyperpigmented skin lesions. Of note, the 
degree of immunosuppression (CD4%) and VL were not associated 
with lung function in this study as in other paediatric adolescent 
studies.[5,22] The origin of the hyperpigmentation is uncertain and 
could represent many causes, such as impetigo, papular pruritic 
eruption and fungal infections. In our experience, papular pruritic 
eruption occurs commonly in HIV-infected children, and it is a 
stage 2 WHO criterion frequently seen with more advanced disease 
and immunosuppression.[23-25] The clinical signs identified could be 
additional pointers to CLD, alerting clinicians to a need for further 
investigation. The absence of a bronchodilator response, in 81.5% in 
our series, has been noted elsewhere and supports the diagnosis of 
non-reversible small-airway disease.[18] 
The role of cART and other medications in managing and 
preventing CLD requires further study. Although the duration of 
cART did not correlate with lung function in earlier studies, it is 
likely that very early initiation will limit development of CLD.[26] 
Despite the limitations in our study, such as no control group 
and a non-random sample with a referral bias, we provide data on 
HIV-related CLD in children, emphasising the ubiquity of poor 
lung function, irreversible in the majority (82%) of children in our 
study. The strength of this study is the use of an objectively assessed 
outcome measure in multivariate analyses, viz. the FEV1. We further 
identified clinical signs associated with poor lung function. 
Conclusion
We documented poor, often irreversible lung function in HIV-infected 
children evaluated for CLD. Easily assessed clinical signs, i.e. respiratory 
rate, hyperinflation and pigmented skin lesions, should alert clinicians to 
considering CLD in HIV-infected children and adolescents. 
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